Cytoki Pharma has initiated a Phase 2 trial of CK-0045, a lipidated IL-22 analogue, in patients with obesity and type 2 diabetes to assess its efficacy and safety.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.